Whether you use whole genome or whole exome technologies, the next-generation sequencing industry continues to face the difficult task of relating NGS data back to affected biology. Ingenuity Variant Analysis solves this problem by allowing researchers to identify causal variants from human resequencing data in just minutes.
A recent article by Genome Web (“The Great Debate Rages On”) discusses the ongoing debate between whole exome and whole genome sequencing. Regardless of the answer you might decide on, the article confirms an even larger challenge – how do you see what all those variants mean in terms of biological effects? How do you interpret that data and identify meaningful variants? Commercial service providers are also recognizing this challenge, which is why several are now offering Ingenuity Variant Analysis as part of their service offerings. Ingenuity Variant Analysis is a new and completely unique web application that helps you rapidly identify causal variants from human resequencing data in just minutes, and has just been launched at the AGBT meeting in Marco Island this week.
Variant Analysis uses a series of filters that you can apply to quickly exclude common variants and non-deleterious variants, and then identify variants that impact symptoms, pathways, processes, or genes implicated in disease progression or drug response. Unlike other software products that focus only on called and annotated variants, Ingenuity Variant Analysis streamlines the annotation and prioritizing of all variants through rich biological interpretation and analysis. Its unique combination of filtering, analytics, and richly annotated content allows you to identify and prioritize variants by drilling down to a small, targeted subset of compelling variants based both upon published biological evidence and your own knowledge of disease biology.
Read the Genome Web article then learn more about at http://www.ingenuity.com/products/ingenuity_variant_analysis.html.